Latest Going Concern News

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Duxton Farms Limited reported a significant half-year loss driven by acquisition and integration costs following a major portfolio expansion. The company is navigating a strategic shift towards diversified agriculture with plans to stabilise earnings over the coming years.

Saferoads Holdings Limited has reported a return to profitability with a $504k half-year net profit, driven by strong product sales following the sale of its Road Safety Rentals business. The company also announced a fully franked interim dividend of 0.5 cents per share.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

US Masters Residential Property Group reported a $57.3 million net loss for 2025 amid a strategic shift to wind down operations by selling its entire US residential property portfolio by the end of 2026. The Group surpassed its aggressive 2025 sales target, setting the stage for capital returns to security holders.

BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.

Australian Dairy Nutritionals Group has cut its net loss by 40% in the half-year to December 2025, driven by a remarkable 431% revenue jump in its nutritional powders segment amid expanding Chinese distribution.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

KKR Credit Income Fund reported a $7.1 million operating profit for the half-year ending December 2025, down sharply from last year, while reinstating its Distribution Reinvestment Plan and maintaining steady monthly distributions.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Cettire Limited reported a 2.8% revenue decline to $382.8 million and a net loss of $1.05 million for the half-year ended 31 December 2025, impacted by softer US demand and rising costs. Despite these headwinds, the company maintains a strong cash position and is focused on profitable growth.